Anavex Life Sciences (AVXL) Competitors $12.13 -0.61 (-4.79%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$12.10 -0.04 (-0.29%) As of 07/25/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL vs. PTCT, ACAD, VKTX, SWTX, AAPG, MLTX, PTGX, HCM, IMVT, and KYMRShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), HUTCHMED (HCM), Immunovant (IMVT), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. Its Competitors PTC Therapeutics ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Ascentage Pharma Group International MoonLake Immunotherapeutics Protagonist Therapeutics HUTCHMED Immunovant Kymera Therapeutics PTC Therapeutics (NASDAQ:PTCT) and Anavex Life Sciences (NASDAQ:AVXL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Do institutionals and insiders have more ownership in PTCT or AVXL? 31.6% of Anavex Life Sciences shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, PTCT or AVXL? PTC Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Does the media prefer PTCT or AVXL? In the previous week, PTC Therapeutics had 4 more articles in the media than Anavex Life Sciences. MarketBeat recorded 8 mentions for PTC Therapeutics and 4 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.28 beat PTC Therapeutics' score of 1.19 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PTCT or AVXL? PTC Therapeutics currently has a consensus price target of $65.00, suggesting a potential upside of 45.28%. Anavex Life Sciences has a consensus price target of $44.00, suggesting a potential upside of 262.74%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PTCT or AVXL more profitable? PTC Therapeutics has a net margin of 33.56% compared to Anavex Life Sciences' net margin of 0.00%. Anavex Life Sciences' return on equity of -40.93% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics33.56% -78.56% 32.11% Anavex Life Sciences N/A -40.93%-36.38% Which has preferable earnings and valuation, PTCT or AVXL? Anavex Life Sciences has lower revenue, but higher earnings than PTC Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M4.40-$363.30M$6.516.87Anavex Life SciencesN/AN/A-$43M-$0.55-22.05 SummaryPTC Therapeutics and Anavex Life Sciences tied by winning 8 of the 16 factors compared between the two stocks. Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09B$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-22.0521.1828.1020.05Price / SalesN/A288.62432.4890.19Price / CashN/A42.7636.2258.56Price / Book8.548.378.665.87Net Income-$43M-$55.19M$3.25B$258.55M7 Day Performance10.47%5.88%4.22%3.73%1 Month Performance26.75%17.33%10.51%11.75%1 Year Performance79.97%4.42%34.40%18.03% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.9003 of 5 stars$12.13-4.8%$44.00+262.7%+77.3%$1.09BN/A-22.0540News CoveragePositive NewsPTCTPTC Therapeutics4.4505 of 5 stars$47.86+0.5%$65.00+35.8%+33.3%$3.79B$806.78M7.351,410News CoverageAnalyst RevisionACADACADIA Pharmaceuticals4.1521 of 5 stars$22.28-1.2%$27.88+25.1%+25.3%$3.73B$957.80M16.26510Positive NewsAnalyst ForecastVKTXViking Therapeutics4.8495 of 5 stars$31.94-0.2%$87.15+172.9%-46.8%$3.59BN/A-27.7720Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSWTXSpringWorks Therapeutics1.349 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230AAPGAscentage Pharma Group InternationalN/A$39.71-1.7%N/AN/A$3.46B$134.35M0.00600Lockup ExpirationGap DownMLTXMoonLake Immunotherapeutics2.1128 of 5 stars$53.57+0.9%$74.50+39.1%+22.6%$3.43BN/A-23.292News CoveragePositive NewsOptions VolumePTGXProtagonist Therapeutics1.3845 of 5 stars$55.22-0.5%$66.10+19.7%+32.7%$3.42B$434.43M73.63120News CoverageInsider TradeHCMHUTCHMED2.7515 of 5 stars$17.74+0.9%$19.00+7.1%-2.2%$3.09B$630.20M0.001,811News CoveragePositive NewsAnalyst ForecastIMVTImmunovant1.2878 of 5 stars$17.70-1.2%$36.30+105.1%-39.0%$3.03BN/A-6.46120News CoverageGap DownKYMRKymera Therapeutics3.0182 of 5 stars$45.14-2.3%$59.11+31.0%+4.0%$2.94B$47.07M-14.56170Positive News Related Companies and Tools Related Companies PTCT Alternatives ACAD Alternatives VKTX Alternatives SWTX Alternatives AAPG Alternatives MLTX Alternatives PTGX Alternatives HCM Alternatives IMVT Alternatives KYMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVXL) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVXL Stock Alerts